Scroll below to view our most recent news releases about Medical and Scientific Information. For philanthropy and event news, click here. Search for all news releases here.

4/30/08 - Researchers develop new ultrasensitive assay to detect most poisonous substance known

Scientists at City of Hope and the California Department of Public Health have developed a new ultrasensitive assay to detect botulinum neurotoxin. The toxin is one of the most poisonous substances known that can cause life-threatening disease, and is considered a major potential bioterrorism threat agent.

4/24/08 - City of Hope Statement Regarding Appeal in Genentech Royalty Case
The California Supreme Court today issued a decision upholding a 2002 jury verdict of $300.1 million in compensatory damages in favor of City of Hope, for Genentech, Inc.’s breach of a 1976 agreement in which City of Hope entrusted a groundbreaking invention to Genentech that launched the biotechnology industry.

4/15/08 - City of Hope researchers present new findings at annual cancer research meeting
Topics include exercise reduces breast cancer risk, novel stem cell-based therapy for brain tumors and clinical trial of Chinese herbal medicine in combination with standard chemotherapy to treat liver cancer

4/14/08 - City of Hope appoints new nursing leadership for all patient care services
City of Hope has named Shirley Johnson, R.N., M.S., M.B.A., a 30-year nursing professional from Barnes-Jewish Hospital in St. Louis, as chief nursing and patient services officer, and Sharon Steingass, R.N., M.S.N., a nursing leader with more than 30 years experience in Southern California-area cancer centers, to vice president of ambulatory services.

4/09/08 - City of Hope names new vice president and chief pharmacy officer

Dale Adams, Pharm. D., has joined City of Hope as vice president and chief pharmacy officer, where he will oversee all pharmacy services as well as radiation oncology services.

4/09/08 - Three industry leaders join City of Hope’s Board of Directors

Communications industry veteran Eddy W. Hartenstein, financial executive Michael E. Keane and health care executive Kathleen McNamara bring their experience and leadership to help guide City of Hope’s growth as a national leader in cancer research, treatment and education.

4/01/08 - City of Hope appoints new senior vice president of research operations
City of Hope has appointed Robert S. Powell as senior vice president of research operations. He will oversee administration of City of Hope’s research programs and support services for the institution’s scientific activities. Additionally, Kristine Justus, Ph.D., has been promoted to vice president of basic research operations and Douglas C. Stahl, Ph.D., to vice president of clinical research operations.

3/20/08 - W. M. Keck Foundation awards grant to continue City of Hope and Caltech collaborative lymphoma study
Researchers from City of Hope and the California Institute of Technology have been awarded a three-year, $1.5 million grant from the W. M. Keck Foundation to continue a collaborative study investigating the molecular mechanisms underlying lymphoma and developing targeted, less-toxic treatments for the disease based on short interfering RNA (siRNA) technology that can inhibit the protein products of specific genes.

3/17/08 - Make a difference in the fight to cure breast cancer!
Thousands of survivors, supporters join City of Hope’s annual Walk for Hope to Cure Breast Cancer in 2008

3/5/08 - City of Hope establishes new Division of Supportive Care Medicine
City of Hope has established a Division of Supportive Care Medicine, which brings all psychosocial support and clinical palliative care programs together under one umbrella. The Division of Supportive Care Medicine will be comprised of a multidisciplinary team including physicians, clinical social workers, psychiatrists, psychologists, physical therapists and chaplains.

1/21/08 - City of Hope appoints distinguished synthetic chemist to chair molecular medicine
David A. Horne, Ph.D., was appointed chair of City of Hope’s Division of Molecular Medicine. As chair, he will lead translational medicinal chemistry research conducted at City of Hope to identify cancer-fighting, small molecule compounds and develop them into novel therapies.

1/14/08 - City of Hope names director of Beckman Research Institute
Richard Jove, Ph.D., a nationally recognized cancer researcher, has been named director of City of Hope’s Beckman Research Institute (BRI). An accomplished scientist, Jove will lead the BRI’s research efforts and facilitate collaborations between basic scientists and physicians to accelerate development of new therapies for cancer, diabetes and other life-threatening diseases.

12/11/07 - Bone marrow transplant patients at increased risk of developing severe or life-threatening medical conditions
While hematopoietic cell transplantation (HCT), also known as bone marrow transplantation, is being increasingly used as a curative treatment for patients with malignant and non-malignant conditions, HCT survivors face increased risk of developing chronic health problems that require life-long medical follow-up.

12/11/07 - City of Hope Praises Childhood Cancer Survivorship Bill
Today, City of Hope praised Congresswoman Hilda Solis (32nd District-CA) and Congresswoman Mary Bono’s (45th District-CA) leadership to introduce the “Pediatric, Adolescent and Young Adult Cancer Survivorship Research and Quality of Life Act of 2007,”  which lays the foundation for increased awareness and federal funding strategies to address the needs of childhood cancer survivors.

12/10/07 - City of Hope researchers developing novel vaccine for bone marrow transplant patients against life-threatening infection
City of Hope researchers have developed and are testing a vaccine for cytomegalovirus (CMV), a serious opportunistic infection that can be life-threatening for people with suppressed or compromised immune systems, such as cancer patients treated with a bone marrow transplant, all solid organ transplant recipients, newborn babies or HIV/AIDS patients.